nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—PTGIR—forebrain—attention deficit hyperactivity disorder	0.0238	0.0729	CbGeAlD
Alprostadil—PTGER1—nervous system—attention deficit hyperactivity disorder	0.0209	0.0641	CbGeAlD
Alprostadil—PTGER1—central nervous system—attention deficit hyperactivity disorder	0.0201	0.0617	CbGeAlD
Alprostadil—PTGIR—cardiovascular system—attention deficit hyperactivity disorder	0.0201	0.0617	CbGeAlD
Alprostadil—SLCO2B1—forebrain—attention deficit hyperactivity disorder	0.0149	0.0456	CbGeAlD
Alprostadil—SLCO3A1—midbrain—attention deficit hyperactivity disorder	0.0139	0.0425	CbGeAlD
Alprostadil—ABCC4—forebrain—attention deficit hyperactivity disorder	0.0132	0.0404	CbGeAlD
Alprostadil—PTGIR—nervous system—attention deficit hyperactivity disorder	0.0129	0.0396	CbGeAlD
Alprostadil—ABCC5—midbrain—attention deficit hyperactivity disorder	0.0125	0.0385	CbGeAlD
Alprostadil—PTGIR—central nervous system—attention deficit hyperactivity disorder	0.0124	0.0381	CbGeAlD
Alprostadil—PTGIR—cerebellum—attention deficit hyperactivity disorder	0.0121	0.0373	CbGeAlD
Alprostadil—SLCO3A1—nervous system—attention deficit hyperactivity disorder	0.0114	0.0349	CbGeAlD
Alprostadil—SLCO2A1—nervous system—attention deficit hyperactivity disorder	0.0113	0.0346	CbGeAlD
Alprostadil—SLCO3A1—central nervous system—attention deficit hyperactivity disorder	0.011	0.0336	CbGeAlD
Alprostadil—SLCO2A1—central nervous system—attention deficit hyperactivity disorder	0.0109	0.0333	CbGeAlD
Alprostadil—SLCO3A1—cerebellum—attention deficit hyperactivity disorder	0.0107	0.0329	CbGeAlD
Alprostadil—PTGIR—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00993	0.0147	CbGpPWpGaD
Alprostadil—PTGIR—brain—attention deficit hyperactivity disorder	0.00986	0.0303	CbGeAlD
Alprostadil—ABCC5—cerebellum—attention deficit hyperactivity disorder	0.00971	0.0298	CbGeAlD
Alprostadil—SLCO3A1—brain—attention deficit hyperactivity disorder	0.0087	0.0267	CbGeAlD
Alprostadil—SLCO2A1—brain—attention deficit hyperactivity disorder	0.00862	0.0265	CbGeAlD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00835	0.0124	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00828	0.0123	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00818	0.0121	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00812	0.012	CbGpPWpGaD
Alprostadil—SLCO2B1—nervous system—attention deficit hyperactivity disorder	0.00807	0.0248	CbGeAlD
Alprostadil—ABCC5—brain—attention deficit hyperactivity disorder	0.00788	0.0242	CbGeAlD
Alprostadil—SLCO2B1—central nervous system—attention deficit hyperactivity disorder	0.00777	0.0239	CbGeAlD
Alprostadil—SLCO2B1—cerebellum—attention deficit hyperactivity disorder	0.0076	0.0233	CbGeAlD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00715	0.0106	CbGpPWpGaD
Alprostadil—ABCC4—nervous system—attention deficit hyperactivity disorder	0.00715	0.0219	CbGeAlD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00713	0.0106	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00701	0.0104	CbGpPWpGaD
Alprostadil—ABCC4—central nervous system—attention deficit hyperactivity disorder	0.00688	0.0211	CbGeAlD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00659	0.00977	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00629	0.00932	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00625	0.00926	CbGpPWpGaD
Alprostadil—SLCO2B1—brain—attention deficit hyperactivity disorder	0.00617	0.0189	CbGeAlD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00596	0.00884	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00567	0.00841	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00564	0.00836	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00564	0.00836	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00559	0.00829	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00552	0.00819	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00552	0.00819	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00548	0.00813	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00548	0.00813	CbGpPWpGaD
Alprostadil—ABCC4—brain—attention deficit hyperactivity disorder	0.00546	0.0168	CbGeAlD
Alprostadil—PTGER2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00545	0.00808	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00534	0.00791	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00495	0.00735	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00486	0.0072	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00483	0.00717	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00483	0.00717	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00473	0.00702	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00473	0.00702	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00461	0.00683	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00459	0.00681	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00451	0.00669	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00446	0.00662	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00438	0.0065	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00433	0.00642	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00428	0.00634	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00424	0.0063	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00422	0.00626	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00417	0.00618	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00403	0.00598	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00395	0.00585	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00383	0.00568	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00383	0.00568	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00382	0.00567	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.0038	0.00564	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00376	0.00558	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00376	0.00557	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00371	0.0055	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0037	0.00549	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00368	0.00546	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00368	0.00546	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00362	0.00537	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0036	0.00535	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0036	0.00535	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00346	0.00513	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00346	0.00513	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00345	0.00512	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00335	0.00496	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00335	0.00496	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.0033	0.0049	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00329	0.00488	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00328	0.00487	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00328	0.00487	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00323	0.00479	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00311	0.00461	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00311	0.00461	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0031	0.0046	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0031	0.0046	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00308	0.00456	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00302	0.00447	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00301	0.00447	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00301	0.00447	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00301	0.00446	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00296	0.00439	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00296	0.00439	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00293	0.00434	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00293	0.00434	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00292	0.00434	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00291	0.00432	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00287	0.00425	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00287	0.00425	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00286	0.00424	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00283	0.00419	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00283	0.00419	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00281	0.00417	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00281	0.00417	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00279	0.00415	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00274	0.00406	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00273	0.00404	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00273	0.00404	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00267	0.00395	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00267	0.00395	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00263	0.0039	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00261	0.00387	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00258	0.00383	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00258	0.00383	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00254	0.00376	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00254	0.00376	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00251	0.00372	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00251	0.00372	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0025	0.00371	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0025	0.00371	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00248	0.00368	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00247	0.00366	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00246	0.00365	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00242	0.00359	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0024	0.00356	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00233	0.00346	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00233	0.00346	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00229	0.0034	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00229	0.00339	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00221	0.00328	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00218	0.00324	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00218	0.00324	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00217	0.00322	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00209	0.0031	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00208	0.00308	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00208	0.00308	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00204	0.00302	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00204	0.00302	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00203	0.00301	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00203	0.00301	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.002	0.00296	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00197	0.00292	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00197	0.00292	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00196	0.00291	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00193	0.00287	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00193	0.00287	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00192	0.00285	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00191	0.00283	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00191	0.00283	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00191	0.00283	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00191	0.00283	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0019	0.00281	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00189	0.0028	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00189	0.0028	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00185	0.00274	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00185	0.00274	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00184	0.00273	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00183	0.00271	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00178	0.00264	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00178	0.00264	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00173	0.00256	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.0017	0.00252	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00166	0.00247	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00166	0.00247	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00166	0.00246	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00165	0.00245	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00164	0.00244	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00164	0.00243	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00164	0.00243	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00162	0.0024	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00162	0.0024	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.0016	0.00237	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STUB1—attention deficit hyperactivity disorder	0.00159	0.00236	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00159	0.00235	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00154	0.00229	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00149	0.00222	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00149	0.00221	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00147	0.00218	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00145	0.00215	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00141	0.00209	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00141	0.00209	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00135	0.002	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0013	0.00193	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0013	0.00193	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00128	0.0019	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00128	0.0019	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00126	0.00187	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00125	0.00185	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00125	0.00185	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00123	0.00183	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00123	0.00183	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.0012	0.00179	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00115	0.0017	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00115	0.0017	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00115	0.0017	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00112	0.00166	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00112	0.00166	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00112	0.00166	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00165	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00165	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00111	0.00165	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00111	0.00165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00109	0.00162	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00109	0.00162	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.00162	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.00162	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00108	0.0016	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00108	0.0016	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00107	0.00159	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00107	0.00159	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00104	0.00155	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00104	0.00155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00104	0.00155	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00103	0.00153	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00101	0.0015	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00101	0.0015	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.001	0.00149	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.001	0.00149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000992	0.00147	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000992	0.00147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00098	0.00145	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000979	0.00145	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000979	0.00145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000946	0.0014	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000912	0.00135	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000912	0.00135	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000911	0.00135	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000882	0.00131	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000867	0.00129	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000857	0.00127	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000835	0.00124	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000798	0.00118	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000792	0.00117	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000792	0.00117	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000779	0.00116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000757	0.00112	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000757	0.00112	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SNAP25—attention deficit hyperactivity disorder	0.000756	0.00112	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000724	0.00107	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000704	0.00104	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000704	0.00104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000662	0.000982	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000662	0.000982	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000639	0.000948	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000639	0.000948	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000633	0.000939	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000615	0.000913	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000615	0.000913	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000602	0.000894	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000596	0.000884	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000596	0.000884	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—EP300—attention deficit hyperactivity disorder	0.00059	0.000875	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000586	0.000869	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000586	0.000869	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000579	0.000858	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000579	0.000858	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000559	0.000829	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000539	0.000799	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000539	0.000799	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—COMT—attention deficit hyperactivity disorder	0.00048	0.000711	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000476	0.000706	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000377	0.00056	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000377	0.00056	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000352	0.000522	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000296	0.000439	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EP300—attention deficit hyperactivity disorder	0.000246	0.000364	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—EP300—attention deficit hyperactivity disorder	0.000206	0.000305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.0002	0.000297	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.0002	0.000297	CbGpPWpGaD
